Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (E

ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ: INHX) announced today the presentation of data from its single ascending dose Phase 1a study of INX-189 in healthy volunteers. The poster presentation will be presented by various scientists from the Company at the 46th European Association for the study of the Liver in Berlin, Germany. The abstract can be viewed at the EASL website at www.easl.eu.

The following poster will be presented during the Viral Hepatitis C: Clinical (Therapy) Poster Session, today, March 31, 2011, from 9:00 am - 6:00 pm CEST.

  • ID #460; Barry et al., “A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS"

The poster will be available in the INX-189 section of the Inhibitex website.

About Inhibitex

Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.



CONTACT:

Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
[email protected]
or
The Trout Group
Lee M. Stern, CFA, 646-378-2922
[email protected]

KEYWORDS:   United States  Europe  North America  Georgia  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Infectious Diseases  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.